During the last few years the treatment landscape of metastatic melanoma has changed dramatically with clinical introduction of targeted therapy and novel immune checkpoint blockade agents. However, acquired resistance to targeted therapy and relatively low response rates to immune therapy poses a major problem. Thus, increased knowledge in melanoma biology and identification of novel therapeutic strategies is a necessity to further increase survival. The main objective of this proposal is to use high throughput genomic technologies to increase our understanding of clinical response to adoptive T cell transfer therapy. We will mainly use whole exome sequencing and RNA sequencing to analyse the data. We plan to sequence tumor and matched normal from 50 patients and according to our experience 5000 core-hours is sufficient. The data involve sensitive data.